Screener
Moderna MRNA Net product sales — Gross product sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Moderna in its filing.
Tagged under the XBRL concept mrna:RevenueFromContractWithCustomerExcludingAssessedTaxGross.
The source filing: Moderna’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001682852-26-000060
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Gross product sales | $350 | $105 |
| Product sales provision: | ||
| Wholesaler chargebacks, discounts and fees | 11 | (22) |
| Returns, rebates and other fees | (9) | 3 |
| Total product sales provision adjustments | $2 | $(19) |
| Net product sales | $352 | $86 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Moderna's net product sales — gross product sales?
- Moderna (MRNA) reported net product sales — gross product sales of $350M in Q1 2026.
- How has Moderna's net product sales — gross product sales changed year-over-year?
- Moderna's net product sales — gross product sales increased by 233.3% year-over-year, from $105M to $350M.
- What is the long-term trend for Moderna's net product sales — gross product sales?
- Over 3 years (2021 to 2025), Moderna's net product sales — gross product sales has grown at a -42.8% compound annual growth rate (CAGR), from $17.68B to $3.31B.
- What does net product sales — gross product sales mean?
- This represents the total invoiced sales of products before any deductions for rebates, chargebacks, discounts, or returns. It provides a view of the total market demand and pricing volume before accounting for contractual adjustments.
Ask your AI about Moderna's net product sales — gross product sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude